Scholarlink

Introduction <p>Lebrikizumab, a human monoclonal antibody that targets interleukin-13, is approved for treating moderate to severe atopic dermatitis in many regions. However, real-world data are lacking and are needed to inform its efficacy and safety in broader populations.</p> Methods <p>This retrospective study reviewed the Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) at baseline and 16–20&#xa0;weeks of 84 consecutive patients who received lebrikizumab subcutaneously at the label dose in a tertiary centre.</p> Results <p>EASI scores were available at 16–20&#xa0;weeks for 72 patients. At this timepoint, 80.6% (58/72) achieved EASI&#xa0;50, 56.9% (41/72) reached EASI&#xa0;75, and 27.8% (20/72) attained EASI&#xa0;90. DLQI was reduced by an average of − 1.5 points at 16–20&#xa0;weeks. No serious adverse events were reported. Ocular adverse events occurred in 21.4% of the cohort (18/84). Eleven out of 14 patients that previously experienced conjunctivitis with dupilumab or tralokinumab had no recurrence with lebrikizumab.</p> Conclusion <p>In this real-world cohort of patients with atopic dermatitis, lebrikizumab demonstrated efficacy comparable to that observed in clinical trials. It may provide an alternative treatment option for individuals who have discontinued other biologics as a result of conjunctivitis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月6日

查看全文
  • Azmeralda Abraheem,
  • Neenu Sebastian,
  • Firas C. Kreeshan,
  • Tim H. Clayton,
  • Hamish J. A. Hunter,
  • Richard B. Warren

摘要

Introduction

Lebrikizumab, a human monoclonal antibody that targets interleukin-13, is approved for treating moderate to severe atopic dermatitis in many regions. However, real-world data are lacking and are needed to inform its efficacy and safety in broader populations.

Methods

This retrospective study reviewed the Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) at baseline and 16–20 weeks of 84 consecutive patients who received lebrikizumab subcutaneously at the label dose in a tertiary centre.

Results

EASI scores were available at 16–20 weeks for 72 patients. At this timepoint, 80.6% (58/72) achieved EASI 50, 56.9% (41/72) reached EASI 75, and 27.8% (20/72) attained EASI 90. DLQI was reduced by an average of − 1.5 points at 16–20 weeks. No serious adverse events were reported. Ocular adverse events occurred in 21.4% of the cohort (18/84). Eleven out of 14 patients that previously experienced conjunctivitis with dupilumab or tralokinumab had no recurrence with lebrikizumab.

Conclusion

In this real-world cohort of patients with atopic dermatitis, lebrikizumab demonstrated efficacy comparable to that observed in clinical trials. It may provide an alternative treatment option for individuals who have discontinued other biologics as a result of conjunctivitis.